R-5780 – UF Innovate https://innovate.research.ufl.edu Building business on innovation Tue, 12 Aug 2025 04:44:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://innovate.research.ufl.edu/wp-content/uploads/favicon-blue_1.png R-5780 – UF Innovate https://innovate.research.ufl.edu 32 32 Rise Therapeutics Receives FDA IND Clearance To Initiate Clinical Testing of R-5780 in Cancer https://innovate.research.ufl.edu/fda-ind-clearance-to-initiate-clinical-testing-of-r-5780-in-cancer/ Wed, 15 Jan 2025 00:00:00 +0000 https://scaddev1.com/fda-ind-clearance-to-initiate-clinical-testing-of-r-5780-in-cancer/ UF startup Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780. This is Rise Therapeutics’ fourth clinical program to enter patient clinical testing. For separate products, other clinical studies are ongoing for the treatment of ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.

Read more about Rise Therapeutics Receives FDA IND Clearance To Initiate Clinical Testing of R-5780 in Cancer. ]]>